Literature DB >> 30001521

Immune Correlate-Guided HIV Vaccine Design.

Galit Alter1, Dan Barouch2.   

Abstract

Although vaccines have been successfully developed against several pathogens, designing an effective vaccine to protect against human immunodeficiency virus (HIV) has remained an intractable challenge. To address this, the research community has looked to human and non-human primate studies to understand the correlates of protective immunity, based on which a targeted vaccine strategy may be designed. Two distinct approaches, focused on different immune correlates of protection, have emerged. The first focuses on structure-based design of HIV envelope immunogens that are able to induce antibodies that neutralize the virus. The second focuses on strategies aimed at driving non-neutralizing polyclonal and polyfunctional antibodies that engage other arms of immunity to clear the virus. Here we review these two different vaccine design strategies and posit that ultimately the convergence of these two efforts will likely be necessary for the development of a globally protective HIV vaccine.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30001521      PMCID: PMC6114134          DOI: 10.1016/j.chom.2018.06.012

Source DB:  PubMed          Journal:  Cell Host Microbe        ISSN: 1931-3128            Impact factor:   21.023


  117 in total

1.  Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice.

Authors:  Devin Sok; Bryan Briney; Joseph G Jardine; Daniel W Kulp; Sergey Menis; Matthias Pauthner; Andrew Wood; E-Chiang Lee; Khoa M Le; Meaghan Jones; Alejandra Ramos; Oleksandr Kalyuzhniy; Yumiko Adachi; Michael Kubitz; Skye MacPherson; Allan Bradley; Glenn A Friedrich; William R Schief; Dennis R Burton
Journal:  Science       Date:  2016-09-08       Impact factor: 47.728

2.  Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.

Authors:  Timothy R Fouts; Kenneth Bagley; Ilia J Prado; Kathryn L Bobb; Jennifer A Schwartz; Rong Xu; Robert J Zagursky; Michael A Egan; John H Eldridge; Celia C LaBranche; David C Montefiori; Hélène Le Buanec; Daniel Zagury; Ranajit Pal; George N Pavlakis; Barbara K Felber; Genoveffa Franchini; Shari Gordon; Monica Vaccari; George K Lewis; Anthony L DeVico; Robert C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-13       Impact factor: 11.205

3.  Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.

Authors:  P W Parren; P A Marx; A J Hessell; A Luckay; J Harouse; C Cheng-Mayer; J P Moore; D R Burton
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

4.  Rational HIV immunogen design to target specific germline B cell receptors.

Authors:  Joseph Jardine; Jean-Philippe Julien; Sergey Menis; Takayuki Ota; Oleksandr Kalyuzhniy; Andrew McGuire; Devin Sok; Po-Ssu Huang; Skye MacPherson; Meaghan Jones; Travis Nieusma; John Mathison; David Baker; Andrew B Ward; Dennis R Burton; Leonidas Stamatatos; David Nemazee; Ian A Wilson; William R Schief
Journal:  Science       Date:  2013-03-28       Impact factor: 47.728

5.  Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity.

Authors:  Stylianos Bournazos; Florian Klein; John Pietzsch; Michael S Seaman; Michel C Nussenzweig; Jeffrey V Ravetch
Journal:  Cell       Date:  2014-09-11       Impact factor: 41.582

6.  Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.

Authors:  Boris Julg; Devin Sok; Stephen D Schmidt; Peter Abbink; Ruchi M Newman; Thomas Broge; Caitlyn Linde; Joseph Nkolola; Khoa Le; David Su; Julia Torabi; Melissa Pack; Amarendra Pegu; Todd M Allen; John R Mascola; Dennis R Burton; Dan H Barouch
Journal:  J Virol       Date:  2017-09-27       Impact factor: 5.103

Review 7.  Immune correlates of vaccine protection against HIV-1 acquisition.

Authors:  Lawrence Corey; Peter B Gilbert; Georgia D Tomaras; Barton F Haynes; Giuseppe Pantaleo; Anthony S Fauci
Journal:  Sci Transl Med       Date:  2015-10-21       Impact factor: 17.956

8.  Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice.

Authors:  Pia Dosenovic; Lotta von Boehmer; Amelia Escolano; Joseph Jardine; Natalia T Freund; Alexander D Gitlin; Andrew T McGuire; Daniel W Kulp; Thiago Oliveira; Louise Scharf; John Pietzsch; Matthew D Gray; Albert Cupo; Marit J van Gils; Kai-Hui Yao; Cassie Liu; Anna Gazumyan; Michael S Seaman; Pamela J Björkman; Rogier W Sanders; John P Moore; Leonidas Stamatatos; William R Schief; Michel C Nussenzweig
Journal:  Cell       Date:  2015-06-18       Impact factor: 41.582

9.  Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs.

Authors:  Sam Hoot; Andrew T McGuire; Kristen W Cohen; Roland K Strong; Lars Hangartner; Florian Klein; Ron Diskin; Johannes F Scheid; D Noah Sather; Dennis R Burton; Leonidas Stamatatos
Journal:  PLoS Pathog       Date:  2013-01-03       Impact factor: 6.823

10.  Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers.

Authors:  Ilja Bontjer; Mark Melchers; Tommy Tong; Thijs van Montfort; Dirk Eggink; David Montefiori; William C Olson; John P Moore; James M Binley; Ben Berkhout; Rogier W Sanders
Journal:  PLoS One       Date:  2013-06-26       Impact factor: 3.240

View more
  24 in total

1.  Antibody-dependent enhancement of influenza disease promoted by increase in hemagglutinin stem flexibility and virus fusion kinetics.

Authors:  Katie L Winarski; Juanjie Tang; Laura Klenow; Jeehyun Lee; Elizabeth M Coyle; Jody Manischewitz; Hannah L Turner; Kazuyo Takeda; Andrew B Ward; Hana Golding; Surender Khurana
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-11       Impact factor: 11.205

Review 2.  Natural Killer Cell Regulation of B Cell Responses in the Context of Viral Infection.

Authors:  Ivayla E Gyurova; Ayad Ali; Stephen N Waggoner
Journal:  Viral Immunol       Date:  2019-12-03       Impact factor: 2.257

Review 3.  On the Road to a HIV Cure: Moving Beyond Berlin and London.

Authors:  Nikolaus Jilg; Jonathan Z Li
Journal:  Infect Dis Clin North Am       Date:  2019-09       Impact factor: 5.982

Review 4.  Immunotherapeutics to Treat HIV in the Central Nervous System.

Authors:  Andrew Kapoor; C Sabrina Tan
Journal:  Curr HIV/AIDS Rep       Date:  2020-10       Impact factor: 5.071

5.  Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV Challenge.

Authors:  Barbara K Felber; Zhongyan Lu; Xintao Hu; Antonio Valentin; Margherita Rosati; Christopher A L Remmel; Joshua A Weiner; Margaret C Carpenter; Katelyn Faircloth; Sherry Stanfield-Oakley; Wilton B Williams; Xiaoying Shen; Georgia D Tomaras; Celia C LaBranche; David Montefiori; Hung V Trinh; Mangala Rao; Munir S Alam; Nathan A Vandergrift; Kevin O Saunders; Yunfei Wang; Wes Rountree; Jishnu Das; Galit Alter; Steven G Reed; Pyone P Aye; Faith Schiro; Bapi Pahar; Jason P Dufour; Ronald S Veazey; Preston A Marx; David J Venzon; George M Shaw; Guido Ferrari; Margaret E Ackerman; Barton F Haynes; George N Pavlakis
Journal:  Cell Rep       Date:  2020-05-12       Impact factor: 9.423

6.  Glycopeptide epitope facilitates HIV-1 envelope specific humoral immune responses by eliciting T cell help.

Authors:  Lina Sun; Amy V Paschall; Dustin R Middleton; Mayumi Ishihara; Ahmet Ozdilek; Paeton L Wantuch; Javid Aceil; Jeremy A Duke; Celia C LaBranche; Michael Tiemeyer; Fikri Y Avci
Journal:  Nat Commun       Date:  2020-05-21       Impact factor: 14.919

Review 7.  Impact of HIV-1 Diversity on Its Sensitivity to Neutralization.

Authors:  Karl Stefic; Mélanie Bouvin-Pley; Martine Braibant; Francis Barin
Journal:  Vaccines (Basel)       Date:  2019-07-25

Review 8.  V2-Specific Antibodies in HIV-1 Vaccine Research and Natural Infection: Controllers or Surrogate Markers.

Authors:  Ralf Duerr; Miroslaw K Gorny
Journal:  Vaccines (Basel)       Date:  2019-08-06

9.  Macrophage-associated wound healing contributes to African green monkey SIV pathogenesis control.

Authors:  Fredrik Barrenas; Kevin Raehtz; Cuiling Xu; Lynn Law; Richard R Green; Guido Silvestri; Steven E Bosinger; Andrew Nishida; Qingsheng Li; Wuxun Lu; Jianshui Zhang; Matthew J Thomas; Jean Chang; Elise Smith; Jeffrey M Weiss; Reem A Dawoud; George H Richter; Anita Trichel; Dongzhu Ma; Xinxia Peng; Jan Komorowski; Cristian Apetrei; Ivona Pandrea; Michael Gale
Journal:  Nat Commun       Date:  2019-11-08       Impact factor: 14.919

10.  Bringing the path toward an HIV-1 vaccine into focus.

Authors:  Cesar J Lopez Angel; Georgia D Tomaras
Journal:  PLoS Pathog       Date:  2020-09-10       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.